Last reviewed · How we verify
Placebo for Sitagliptin
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in Phase 3 clinical trial for Sitagliptin (type 2 diabetes mellitus).
At a glance
| Generic name | Placebo for Sitagliptin |
|---|---|
| Also known as | Placebo |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. In this Phase 3 trial, the placebo serves as the comparator arm against Sitagliptin (a DPP-4 inhibitor used for type 2 diabetes). Any observed effects in the placebo group are attributed to the placebo effect or natural disease progression.
Approved indications
- Control arm in Phase 3 clinical trial for Sitagliptin (type 2 diabetes mellitus)
Common side effects
Key clinical trials
- Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data
- Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data
- Anti-Diabetic Medications to Fight PD and LBD (PHASE4)
- Effects of Sitagliptin in Individuals With Genetically Decreased DPP4 (PHASE4)
- iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD) (PHASE3)
- DPP4-Inhibitors and Bone Metabolism in Diabetes (PHASE3)
- A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes (PHASE3)
- Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Sitagliptin CI brief — competitive landscape report
- Placebo for Sitagliptin updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI